Carbapenemase-producing Organisms (CPO) Protocol
Contents

INTRODUCTION ........................................................................................................................................ 4
GOAL ..................................................................................................................................................... 4
OBJECTIVES ....................................................................................................................................... 4
METHODOLOGY .................................................................................................................................... 5
  PATIENT POPULATION .................................................................................................................... 5
CASE DEFINITION ............................................................................................................................... 5
  INCLUSION CRITERIA .......................................................................................................................... 5
  EXCLUSION CRITERIA .......................................................................................................................... 6
CASE CLASSIFICATION ....................................................................................................................... 6
  HOSPITAL-ACQUIRED ......................................................................................................................... 6
  HOSPITAL-IDENTIFIED ....................................................................................................................... 6
  ON ADMISSION ................................................................................................................................... 7
  OTHER CONSIDERATIONS FOR CLASSIFICATION ......................................................................... 7
  READMISSIONS WITHIN 12 MONTHS OF KNOWN EPIDEMIOLOGICAL LINK AND NO TRAVEL HISTORY ....................................................................................................................... 7
  BSI WITH CPO SURVEILLANCE ....................................................................................................... 7
  CPO IDENTIFIED IN SURGICAL SITE INFECTIONS (SSI) ............................................................. 7
  RISK FACTORS .................................................................................................................................. 8
DATA COLLECTION AND DATA ENTRY ............................................................................................. 8
  MANDATORY DATA ENTRY ................................................................................................................ 8
  MINIMUM CASE INFORMATION ......................................................................................................... 9
DENOMINATOR DATA .......................................................................................................................... 9
RATE CALCULATIONS ........................................................................................................................ 10
COMPARATOR RATES ........................................................................................................................ 10
REPORTING .......................................................................................................................................... 10
DATA QUALITY ..................................................................................................................................... 10
PROTOCOL REVISION HISTORY ..................................................................................................... 12
REFERENCES ......................................................................................................................................... 13
APPENDIX A: CPO PROTOCOL-SPECIFIC DEFINITIONS .............................................................. 14
APPENDIX B: GENERAL SURVEILLANCE DEFINITIONS ............................................................. 17
APPENDIX C: CPO CLASSIFICATION ALGORITHM ........................................................................ 19
Introduction

Gram-negative bacilli including Enterobacteriaceae, *Pseudomonas* species and *Acinetobacter* species are common pathogens found in some hospitalized patients. These organisms primarily cause urinary tract infections, ventilator-associated pneumonia, and wound infections and may progress to bloodstream infections. Multi-drug resistant gram-negative bacilli are an emerging problem because infections caused by these organisms are unable to be treated with usual first-line antibiotics and can cause increased morbidity and mortality in patients.

Carbapenem-resistant organisms are usually resistant to all penicillins, cephalosporins and carbapenems. Their resistance is mediated by a number of mechanisms, one of which is the presence of an inactivating enzyme (a carbapenemase) which is detected using specific gene-detection laboratory tests. Three classes of acquired carbapenemases are found in Enterobacteriaceae, *Pseudomonas* species, and *Acinetobacter* species (Gupta, Limbago, Patel, & Kallen, 2011). Unlike organisms resistant to carbapenems through other mechanisms, carbapenemase-producing organisms (CPOs) have been prone to spread within healthcare facilities. Factors affecting the emergence and spread of CPOs include cross-border movement of patients due to travel, medical tourism and as refugees (Canton et al., 2012).

When using this protocol, each CPO episode (infection or colonization) will be considered separately and the rules of the protocol will be applied independently for each. Surveillance rates will be reported at the patient-level, e.g., each time the patient is identified with a new CPO episode, the patient will be identified as a separate incident case regardless of the number of new organisms isolated at that time.

There are three supporting tools to assist in the interpretation and practical use of the protocol – CPO Protocol-Specific and General Surveillance Definitions (Appendix A and Appendix B), the CPO Case Classification Algorithm (Appendix C), and the ProvSurv User Guide (Alberta Health Services [AHS], 2018).

Goal

To monitor hospital-acquired, hospital-identified and CPO identified on admission in Alberta Health Services (AHS) and Covenant Health facilities.

Objectives

1. To determine the incidence of recognized hospital-acquired, hospital-identified, and on admission CPO colonization and infections in the population under surveillance in AHS/Covenant Health facilities, and to collect information on patient risk factors to describe the emerging epidemiology of CPO in Alberta.
2. To use surveillance results to develop and evaluate Infection Prevention and Control (IPC) interventions which support safer patient care.
3. To establish quarterly and annual CPO incidence rates for trend analysis over time and to compare with internal and external benchmarks.
4. To establish incidence rates of bloodstream infections (BSI) with CPO.
Methodology

- Cases eligible for surveillance are inpatients with laboratory confirmed CPO.
- Reports of isolates originating from facilities under surveillance will be forwarded by laboratories to site based IPC programs or designates. Confirmation must be obtained at the reporting facility where the patient is an inpatient, except in the case of admission screening of direct patient transfers within provincial facilities under surveillance where acquisition is being attributed to the sending facility.
- Facility Infection Control Professionals (ICP) receiving CPO laboratory reports will determine if cases are hospital-acquired, hospital-identified, or on admission and compile and record at least the minimum case information. Data from completed CPO surveillance will be entered into the provincial surveillance data management system (ProvSurv) in a timely manner.

Patient population

All individuals admitted to AHS/Covenant Health acute and acute tertiary rehabilitation care facilities where inpatient care is provided 24 hours/day, 7 days a week. Acute and acute tertiary rehabilitation facilities will be referred as the “facilities under surveillance” in this protocol for simplicity. Refer to Appendix B: General surveillance definitions for facilities that would be included under this term.

Case definition

Each incident (Initial) case is the presence of one (1) or more lab confirmed new CPOs from a body site; and

Is identified as positive with a CPO at the time of admission or during hospitalization.

Inclusion criteria

- Patients with lab-confirmed isolate(s) of Enterobacteriaceae, *Pseudomonas aeruginosa* or *Acinetobacter* species with acquired carbapenemase meeting the Alberta Health definition and confirmed to have a carbapenemase by molecular methods (Alberta Health, 2018).
- Previously known CPO positive patients with a different organism which produces a carbapenemase (i.e., a new Initial/incident case if the patient acquired another CPO with a different organism identified).

A new Initial (incident) case is based on a patient having a culture positive for a new carbapenemase producing organism not the same organism previously identified as a CPO which has acquired another carbapenemase producing gene, e.g.,:

- A patient identified with an *E.coli* with a KPC gene and an *Acinetobacter* species with an OXA gene in the same episode would be a single incident case.
- If the patient is later identified with an *E.coli* that has both KPC and NDM (i.e., – new genes are detected) this would **not** be another incident case, because the same organism is isolated.

If the same patient is later identified with a *Klebsiella* species that has a KPC gene, this would be a second incident case because a new organism has been identified.

Once a particular CPO has been identified (i.e., there is an Initial record), subsequent data entries for infections or colonizations with that organism would be entered as Follow-up records in the data entry system (ProvSurv).
Exclusion criteria

- Patients with laboratory confirmed CPO who were not admitted at the time of specimen collection or were not subsequently admitted as an inpatient following their emergency department visit are not eligible to be an Initial case.
- While these are not surveillance cases, they should still be recorded as For Info cases.

Case classification

Once the patient has been identified as an incident CPO case, he/she will be classified as hospital-acquired, hospital-identified, or on admission. For all case classifications, additional risk factor information will be collected to better understand the emerging epidemiology for these organisms in Alberta. Case classification is based on the following criteria:

Hospital-acquired

- Incident CPO on any day of admission based on an assessment by the ICP using a case believed to be epidemiologically linked to another person(s) with a CPO infection or colonization in the current facility admission (e.g., shared same room, same ward/unit, same caregiver, or same procedure/surgery as a known patient/resident with the same CPO);
  or
- The specimen collection date of the incident CPO occurs during a hospital admission within 12 months of an epidemiological link in a previous admission to any AHS/Covenant Health facility.

Direct transfers between facilities

- If a patient not known to be CPO positive is transferred directly from one AHS/Covenant Health acute or acute rehabilitation care facility to another and is identified positive by the receiving facility, the sending facility must be notified of the CPO to determine the case classification.
- The sending facility records the case as hospital-acquired or hospital-identified to their facility if the CPO does not have an epidemiological link to another AHS/Covenant Health facility within the past 12 months.

Hospital-identified

Incident CPO on or after the 3rd calendar day of admission based on an assessment by the ICP using the following criteria:

- No known CPO colonization or infection at time of admission;

and

- No established epidemiological link to another person(s) with a CPO infection or colonization for the same organism at the current facility or any AHS/Covenant Health facility in the 12 months prior to specimen collection date.
On admission
Incident CPO on the day of admission (calendar day 1) and/or the day after admission (day 2) based on an assessment by the ICP using the following criteria:

- Does not meet definition for hospital-acquired or hospital-identified;

and

- No established epidemiological link to another person(s) with a CPO infection or colonization at the current facility or any AHS/Covenant Health facility in the 12 months prior to specimen collection date.

Other considerations for classification

- Site of positive culture as an Initial case - If a patient has multiple body sites positive with the same CPO within one (1) day of each other, use the culture result with the most significant manifestation of the organism (i.e., most clinically relevant specimen) to report as the Initial record. If the patient has an infection and colonization within one day of each other, the infection should be captured as the Initial case. e.g., if blood and wound culture specimens are positive within one day of each other, the blood specimen should be used when creating the Initial case.

- If specimens were collected more than one (1) day apart use the specimen with the earliest collection date as the incident case.

Readmissions within 12 months of known epidemiological link and no travel history

- If a patient (not known to be CPO positive) is admitted to a facility under surveillance, has a known epidemiological link to another facility (in the last 12 months) and is identified with a CPO infection or colonization on admission (i.e., prior to calendar day 3), the Infection Control Professional at the epidemiological link facility must be notified of the CPO to agree with the interpretation of the case classification. The ICP at the admitted facility creates a For Info record using the encounter information of their facility and sends invite to ICP at the epidemiological link facility.

- If the ICP at the epidemiological link facility confirms that there was an epidemiological link at their facility and the case is hospital-acquired to their facility, further data entry will be performed with the help of the Surveillance and Standards team.

BSI with CPO surveillance

- All BSI records for a CPO under surveillance are to be entered into the ProvSurv BSI module even for sites that are not performing local BSI surveillance.

- For BSI with CPO, the case classification for BSI and CPO are determined independently. Classify the CPO based on the CPO protocol and the BSI based on the BSI protocol.

Note: Each new BSI with CPO episode must be entered in ProvSurv but not every positive blood culture result from the same BSI episode. Please refer to the provincial BSI protocol for more information (AHS, 2020).

- Any new hospital-acquired BSI where the pathogen is CPO is included in the hospital-acquired BSI with CPO rate. This is regardless of the status of the CPO (either Initial or Follow-up). The event is reported in the reporting quarter of the BSI event date.

CPO identified in surgical site infections (SSI)

- If a patient has a CPO positive culture from a SSI and is deemed to be a SSI (according to the National Healthcare Safety Network Surgical Site Infection definitions (Centers for Disease Control and Prevention [CDC], 2020a)), that information should be entered independently in the ProvSurv CPO module and into the ProvSurv SSI module if the surgical procedure is one followed for either provincial or local SSI surveillance.
• If a CPO is identified from a superficial incisional SSI (infection is occurring within 30 days of the surgery), the Initial CPO case will be classified according to the criteria for case classifications above.

• If a CPO Initial case is identified from a deep incisional or organ-space SSI it will be classified according to the following criteria:
  o If the surgery resulted in a deep or organ-space SSI, the CPO Initial case will be hospital-acquired to the facility where the surgery was done if infection occurs within their National Healthcare Safety Network Surgical Site Infection defined Follow-up time. The procedure facility and surgery admission date should be used as the Encounter information for that record and the ICP at that facility should be notified of the CPO to agree with the interpretation of the National Healthcare Safety Network definition.
  o Any SSIs identified outside of the Follow-up time and within 12 months will be classified according to the criteria for case classifications above.

Risk factors

The following risk factors must be reported for hospital-identified and on admission CPO cases:

Acquired-outside Alberta (in past 12 months)

• Healthcare exposures outside Alberta (e.g., medical tourism, unexpected hospitalization, or returning military personnel that received medical care outside Alberta);
  or

• Travel/residency outside Alberta with no healthcare exposures.

Epidemiological link in Alberta (in past 12 months)

• Community (e.g., household contact of known CPO positive patient, or no other identified risk factors).
  • Does not include epidemiological links to AHS/Covenant Health facilities.

AHS/Covenant Health healthcare exposures (in past 12 months)

• Previous admission to an AHS/Covenant Health facility for more than or equal to 3 calendar days with no known CPO epidemiological link.
• In the past 12 months was a resident at a long-term care facility.
• Has indwelling catheter or medical device at the time of culture that is externally exposed and can be manipulated for care on a regular basis.
• In the past 12 months was known to have a surgical procedure, peritoneal dialysis or hemodialysis.

Data collection and data entry

Mandatory data entry

• Incident CPO laboratory episodes of an admitted patient in all AHS/Covenant Health facilities under surveillance.
• Case severity decisions for each case should be noted using National Healthcare Safety Network infection definitions.
• All inpatient blood cultures growing CPO from facilities under surveillance must be evaluated and if determined to be a New BSI episode it must be entered directly in the ProvSurv CPO module and BSI module regardless of the CPO record type (Initial, For Info, Follow-up).
Minimum case information

Basic demographic, facility and microbiological data will be collected on all cases and must include:

- Name (first, middle and last);
- Date of birth;
- Gender;
- Alberta Personal Healthcare Number (PHN) (or Unique Lifetime Identifier (ULI));
- Record type and case classification (i.e. hospital-acquired, hospital-identified, on admission);
- Admission date to reporting facility;
- Reporting zone and facility name;
- Encounter service and area where patient is admitted;
- Culture date, laboratory name, accession number, and cultured site;
- Case severity (colonization/infection);
- Specimen sampling reason;
- Healthcare and Travel Risk Factors (where this information is available in the patient record). Includes multiple healthcare exposures in past 12 months, epidemiological link – community (e.g., household contact of CPO patient); travel history outside Alberta in past 12 months with no healthcare exposure; or type of healthcare contact outside Alberta in past 12 months;
- Subsequent isolates for known CPO patients where a new CPO gene is detected in the same organism strain as previously identified. For example – the initial *Klebsiella pneumoniae* has an NDM, and later strain is *Klebsiella pneumoniae* with NDM and OXA- enter the second isolate as a Follow-up record.

Other considerations for data entry

- Information may be obtained from a variety of sources including inpatient/resident charts (current or archived), nurses' logs, laboratory reports, nursing and medical staff, etc. The data will be collected by the ICP manually or electronically as soon as possible after the lab report of the initial CPO isolate is obtained.

- Each ICP or IPC designate will be responsible for timely entry of the surveillance data into ProvSurv. It is expected that the minimum data set is collected and entered into ProvSurv in a timely manner after factoring in time of collection, to time to reach laboratory, work-up and distribution to ICP and/or IPC offices.

- As a recommendation, data entry should be completed within 1-2 weeks of receiving the laboratory report by an ICP or an IPC designate.

Denominator data

Denominators (numbers of inpatient admissions and inpatient days) are provided by AHS Analytics. Denominators are presented by month, which are aggregated for the fiscal quarter of the report. Denominators used for reporting can be accessed on Tableau Workbooks through SharePoint.
Rate calculations

<table>
<thead>
<tr>
<th>Incidence rates for AHS/Covenant Health hospitalized patients</th>
<th>Calculations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital-acquired CPO</td>
<td>Number of hospital-acquired CPO cases x 10,000</td>
</tr>
<tr>
<td></td>
<td>Number of patient-days</td>
</tr>
<tr>
<td>Hospital-identified CPO</td>
<td>Number of hospital-identified CPO cases x 10,000</td>
</tr>
<tr>
<td></td>
<td>Number of patient-days</td>
</tr>
<tr>
<td>On admission CPO</td>
<td>Number of on admission CPO cases x 1,000</td>
</tr>
<tr>
<td></td>
<td>Number of admissions</td>
</tr>
<tr>
<td>Total CPO</td>
<td>Total Number of CPO cases x 1,000</td>
</tr>
<tr>
<td></td>
<td>Number of admissions</td>
</tr>
</tbody>
</table>

Comparator rates

Internal and external surveillance rates are used as comparators. The internal rates are the historical rates for the province or zone from the previous fiscal year. The external rates are provided by the Canadian Nosocomial Infection Surveillance Program (CNISP) which are created from data submitted by large and tertiary acute care facilities and therefore may not provide appropriate comparison for smaller acute care facilities.

Reporting

Communication and dissemination of surveillance reports is an integral part of surveillance, to inform IPC practice within AHS/Covenant Health and provide support for interventions that improve the quality of patient care delivered. Responsibility for compiling, reporting, and disseminating data and reports is shared between AHS/Covenant Health IPC Surveillance and Standards and the AHS/Covenant Health IPC program. Formal reports are generated routinely (usually quarterly) using reconciled and validated data. The reports contain information on the site, zone and provincial level and are presented to the provincial IPC Surveillance Committee for approval (AHS, 2019).

Operational reports are created by local ICP or their designate and may or may not consist of reconciled and validated data, as they are often created with real-time, as is, data. Additional BSI with antibiotic-resistant organism information can be accessed on our Tableau Workbooks through SharePoint.

Outbreak reporting

Real-time reporting and critical threshold reporting is available to ICP from ProvSurv for immediate management of detected outbreaks. Since CPO is unusual in Alberta, all CPO cases will be reviewed. Two or more of the same CPO clustered in time or place should be considered an outbreak and should prompt investigation and intervention relative to potential or determined causative factors.

Data quality

The purpose of evaluating the quality of data is to ensure that surveillance-related events are being monitored efficiently and effectively. The evaluation should involve the assessment of the program (i.e., the protocol and reporting) and system (i.e., electronic data collection tool) attributes, including relevance, simplicity, flexibility, data quality, acceptability, consistency, representativeness, timeliness and stability. Additionally, with the increasing use of technology, informatics concerns for surveillance systems need to be addressed. These include evaluating hardware and software, using a standard user interface, applying
standard data formatting and coding, performing quality checks and adhering to confidentiality and security standards.

A standardized approach is used to reconcile and validate the data provincially. The first component of data reconciliation and validation of data in ProvSurv ensures that demographic data are valid and reliable. The second component entails ensuring that the surveillance-related events are entered in a manner that is consistent with the protocol definitions. At this latter stage, outliers are identified and requests are sent to the ICP to verify that the data was correctly entered and the definitions were consistently applied according to the provincial surveillance protocol. Final designation of cases is a collaborative effort between the facility-based ICP and the epidemiologists/analysts of the IPC Surveillance and Standards team.

Further use of statistical software for validating records is still in development. Algorithms are continuously being updated and added to ensure capture of as many discrepancies as possible. In addition to this current process of data review, there will be data audits using external data sources to determine the validity and reliability of the data in ProvSurv. The data in ProvSurv will also serve to inform decisions made by the IPC Surveillance and Standards team to improve surveillance processes and methodologies.

On-going case-severity decision reviews are conducted to create a supportive environment for the ICP and IPC physicians at the facilities, and to create mentoring relationships between Data Quality Working Group members and ICP at these facilities to support all aspects of surveillance across the participating facilities.

Data quality working group

The IPC Surveillance Data Quality Working Group reports to the IPC Surveillance committee and is responsible to develop, review and update indicator protocols to include the precise methodology for data collection to ensure consistency. Decisions from the Data Quality Working Group on specific protocol questions are communicated to provincial ICP through the Data Quality Forum and will be included in the protocol User Guide. These decisions will be considered to be supplemental to the protocol and will be incorporated into the protocol when revised.
## Protocol revision history

<table>
<thead>
<tr>
<th>Date</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2012</td>
<td>Protocol approved by Surveillance Committee.</td>
</tr>
<tr>
<td>March 2017</td>
<td>Revised.</td>
</tr>
<tr>
<td>March 2018</td>
<td>Revised.</td>
</tr>
<tr>
<td>March 2019</td>
<td>Revised HA definition to align with flowchart, protocol style updated, reference style changed to APA).</td>
</tr>
<tr>
<td>Spring 2020</td>
<td>Added link to AB Health definition of CPO. Updated to new template and reposted to web page.</td>
</tr>
</tbody>
</table>
References


## Appendix A: CPO protocol-specific definitions

<table>
<thead>
<tr>
<th>Terms</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbapenem-producing organism case definition</td>
<td>Laboratory confirmation of a carbapenemase by molecular methods in any carbapenem non-susceptible (includes intermediate and complete resistance to the carbapenems according to the most current clinical and Laboratory Standards Institute interpretive breakpoint guidelines) <em>Enterobacteriaceae</em> or <em>Acinetobacter</em> (Alberta Health, 2018).</td>
</tr>
<tr>
<td>Body or culture sites examples</td>
<td>Abscess, Bronchoalveolar lavage (BAL)-Bronchial Wash (BW), Blood, Burn, CSF Fluid, Device Insertion Site, Groin, Nose, Nose-Groin, Nose-Rectal, Pleural Fluid, Rectal-Stool, Skin, Soft Tissue, Sputum, Stoma, Surgical Site, Synovial Fluid, Throat, Ulcer, Urine, Wound.</td>
</tr>
<tr>
<td>Calendar days</td>
<td>Used for determining the timeline of presenting with or acquiring an antibiotic-resistant organism, CDI, BSI, or National Healthcare Safety Network infection definition. Calendar day one is the day of patient admission (see patient admission definition for more information) or day of surgical procedure.</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>These include agents such as ertapenem, meropenem, imipenem and doripenem. These are beta-lactam antibiotics (as are penicillins and cephalosporins) that are used to treat serious infections caused by gram negative organisms such as <em>Enterobacteriaceae, Acinetobacter</em> species and <em>Pseudomonas</em> species.</td>
</tr>
<tr>
<td>Carbapenemase</td>
<td>These are enzymes that inactivate carbapenem agents and cause those organisms to be non-susceptible (intermediate or resistant), and therefore may result in treatment failure.</td>
</tr>
<tr>
<td>Acquired carbapenemases</td>
<td>Additional genes that the organism has obtained through contact with other organisms with these genes: the genes transfer between organisms. There are three classes of acquired carbapenemase in <em>Enterobacteriaceae, Pseudomonas</em> species and <em>Acinetobacter</em> species (Canton et. al., 2012). Please refer to phenotypic testing definition below. If you have further questions please refer to the Alberta Health definition.</td>
</tr>
<tr>
<td></td>
<td>• Class A (KPC types, first found in Klebsiella, also see in E.coli)</td>
</tr>
<tr>
<td></td>
<td>• <em>KPC</em>: Klebsiella pneumoniae carbapenemase</td>
</tr>
<tr>
<td></td>
<td>• Class B (metallo-beta-lactamases such as VIM, IMP in <em>Pseudomonas</em> species; and NDM now seen in Enterobacteriaceae)</td>
</tr>
<tr>
<td></td>
<td>• <em>VIM</em>: Verona-integron coded metallo-beta-lactamase <em>IMP</em>: integron mediated plasmid <em>NDM</em>: New Delhi beta-lactamase</td>
</tr>
<tr>
<td></td>
<td>• Class D (oxacilinases – OXA, first seen in Klebsiella species) <em>OXA</em>: oxacillin beta-lactamase</td>
</tr>
<tr>
<td>Carbapenemase-producing organisms (CPO)</td>
<td>An organism that is non-susceptible to carbapenem agents because it produces carbapenemase (the enzyme which deactivates carbapenems) due to the presence of acquired gene(s) coding for these enzymes.</td>
</tr>
<tr>
<td>Colonization</td>
<td>The presence of microorganisms on skin, on mucous membranes, in open wounds, or in excretions or secretions but are not causing adverse clinical signs or symptoms (CDC, 2020b).</td>
</tr>
<tr>
<td>Dialysis</td>
<td>Hemodialysis patients require a vascular access, which can be a catheter or a graft or enlarged blood vessel that can be punctured to remove and replace blood. Peritoneal dialysis works on the same principle as hemodialysis, but the blood is cleaned while still inside the patient’s body, rather</td>
</tr>
<tr>
<td>Terms</td>
<td>Definitions</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>than in a machine. A catheter is surgically inserted in the abdomen, usually below and to one side of the navel. Because of frequent hospitalizations and receipt of antimicrobial drugs, dialysis patients are also at high risk for infection with antimicrobial-resistant bacteria (CDC, 2018; The Kidney Foundation of Canada, n.d.).</td>
<td></td>
</tr>
<tr>
<td>Enterobacteriaceae</td>
<td>Gram negative coliforms, typically found in the human gastrointestinal system. <em>E. coli</em> and <em>Klebsiella pneumoniae</em> are the most commonly seen CPO of this family. Other genera include: Citrobacter, Enterobacter, Hafnia, Morganella, Proteus, Providencia, and Serratia. Uncommon human isolates are Edwardsiella, Erwinia, Klyuvera, Pantoeae, Raoultella and common food-borne pathogens such as Salmonella, Shigella and Yersinia.</td>
</tr>
<tr>
<td>Epidemiological link</td>
<td>A case is thought to be epidemiologically linked to another person(s) or healthcare worker(s) with a CPO infection or colonization in a facility (e.g. shared same room, same ward/unit, same caregiver, and same procedure/surgery as a known patient/resident with the same CPO).</td>
</tr>
<tr>
<td>Genotypic testing</td>
<td>Laboratory methods used to test for the presence of a gene. Methods include pulse field gel electrophoresis or polymerase chain reaction. While phenotypic testing would determine if an organism is susceptible or non-susceptible to an antimicrobial agent, genotypic testing can determine if a gene is present which may deactivate the agent, whether or not it is expressed.</td>
</tr>
<tr>
<td>Indwelling catheter</td>
<td>A drainage tube that is inserted into the urinary bladder through the urethra, is left in place, and is connected to a closed collection system. It is also called a Foley catheter. It does not include straight in and out catheters or urinary catheters that are not placed in the urethra (e.g., suprapubic catheter) (CDC, 2020c).</td>
</tr>
<tr>
<td>Medical device</td>
<td>Covers a wide range of products used in the treatment, mitigation, diagnosis or prevention of a disease or abnormal physical condition (Health Canada, 2014). Examples to consider when determining whether an incident MRSA case is classified as healthcare-associated include: central venous catheters (CVCs), intravenous lines, peripheral, umbilical catheters, peripherally inserted central catheter, stoma, and trach.</td>
</tr>
<tr>
<td>Molecular methods</td>
<td>Genetic test methods to confirm the presence of a specific gene. One example is genetic testing for the presence of specific genes that produce carbapenemases. For further details, review this specific test method on the Centers for Disease Control website: <a href="http://www.cdc.gov/HAI/settings/lab/kpc-ndm1-lab-protocol.html">http://www.cdc.gov/HAI/settings/lab/kpc-ndm1-lab-protocol.html</a> (CDC, 2011).</td>
</tr>
<tr>
<td>Non-susceptible</td>
<td>Non-susceptible organisms include those which have intermediate or complete resistance to the antimicrobial agent or class of agents (e.g., carbapenems) according to the most current Clinical and Laboratory Standards Institute (CLSI) interpretive breakpoint guidelines. If an organism is non-susceptible to a particular antibiotic class (e.g., aminoglycosides, cephalosporins) then all antibiotics in that class that are tested are non-susceptible or should be considered to be ineffective for treatment if indicated in laboratory reporting comments.</td>
</tr>
<tr>
<td>Terms</td>
<td>Definitions</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Phenotypic testing</strong></td>
<td>Refers to the observable physical or biochemical characteristics of an organism. One example is antimicrobial susceptibility testing, where an organism is tested against a known concentration of an antimicrobial to determine the Minimum Inhibitory Concentration of the agent required to prevent growth of the organism. Using these concentrations, the laboratory can determine if the organism is susceptible (able to be used for clinical treatment) or non-susceptible (levels of the agent needed to inhibit the organism are higher than therapeutic levels of the agent and may result in treatment failure if used).</td>
</tr>
<tr>
<td><strong>Secondary phenotypic testing</strong></td>
<td>Laboratory testing methods using additional lab test methods to screen for the presence of a genotypic characteristic. According to the Alberta Health CPO lab definition, this testing is required to confirm the presence of a CPO in an <em>Enterobacteriaceae</em> or <em>Pseudomonas aeruginosa</em>, e.g., lab test for CPO called a modified Hodge Test.</td>
</tr>
</tbody>
</table>
### Appendix B: General surveillance definitions

<table>
<thead>
<tr>
<th>Terms</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Encounter types</strong></td>
<td>Type of AHS/Covenant Health healthcare location or facility where the patient is located at the time of identification. The following encounter types are referred to in acute care surveillance protocols (Government of Alberta, 2008; Government of Alberta, 2020).</td>
</tr>
<tr>
<td><strong>Continuing care</strong></td>
<td>An integrated range of services supporting the health and wellbeing of individuals living in their own home, a supportive living or long-term care setting. Continuing care clients are not defined by age, diagnosis or the length of time they may require service, but by their need for care.</td>
</tr>
<tr>
<td><strong>Continuing care/long-term care</strong></td>
<td>Long term care facilities include auxiliary hospitals and nursing homes reserved for those with unpredictable and complex health needs who require 24-hour nursing care. Residents of long-term care facilities usually have multiple chronic and/or unstable medical conditions. Specialized services such as respite, palliative care, case management, rehabilitation therapy, as well as services for advanced Alzheimer’s and dementia are available at these facilities.</td>
</tr>
<tr>
<td><strong>Auxiliary hospital</strong></td>
<td>A facility designated for the provision of medical services to in-patients who have long-term or chronic illnesses, diseases or infirmities. Services may include acute palliative programs, geriatric day programs or day/night programs. They may include functional centres such as long-term care, medical or clinical areas.</td>
</tr>
<tr>
<td><strong>Nursing home</strong></td>
<td>A facility where medical services are provided to long term patients.</td>
</tr>
<tr>
<td><strong>Emergency</strong></td>
<td>Emergency Departments take care of people that are very sick or injured on a priority basis by providing medical care, which may include assessment, treatment, stabilization to prepare people for transport to a higher level of care facility (if needed) and Follow-up care, including referrals to a family doctor or specialist (if needed). This option can be used to capture outpatient encounters when a patient visited the emergency department at a facility and did not subsequently get transferred to an inpatient unit, but rather returned back to his/her home setting.</td>
</tr>
<tr>
<td><strong>Inpatient acute care</strong></td>
<td>Refers to a General Hospital: According to the Hospitals Act, a general hospital is defined as a “hospital providing diagnostic services and facilities for medical or surgical treatment in the acute phase for adults and children and obstetrical care” (Government of Alberta, 2020). General hospitals have several functional centres. Each functional centre is associated with in-patient, outpatient, or diagnostic and therapeutic services.</td>
</tr>
<tr>
<td><strong>Inpatient mental health/rehab</strong></td>
<td>A designated mental health facility providing diagnosis and treatment for mental illness and addiction in the acute phase for adults and children. Inpatient services refer to a person admitted to and assigned a bed in a facility by order of a physician for provision of diagnostic and/or treatment services. They would have a patient/group room in which inpatient services are provided within the patient’s room or within a common group room within the designated mental health facility. AHS facility examples include Glenrose Rehabilitation Hospital, Centennial Centre for Mental Health and Brain Injury.</td>
</tr>
<tr>
<td><strong>Infection window period</strong></td>
<td>The 7-days during which all site-specific infection criteria must be met. It includes the day of the first positive diagnostic test (i.e., lab specimen collection, imaging test, procedure or exam, physician diagnosis and initiation of treatment) that is an element of the site-specific infection criterion, was obtained, the 3 calendar days before and the 3 calendar days after. For site-specific infection criteria that do not include a diagnostic test, the first documented localized sign or symptom that is an element of National Healthcare Safety Network infection criterion,</td>
</tr>
</tbody>
</table>
### Terms and Definitions

<table>
<thead>
<tr>
<th>Terms</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>excluding SSIs, should be used to define</td>
<td>the window (i.e., diarrhea, site specific pain, purulent exudate).</td>
</tr>
<tr>
<td>Infection prevention and control baseline</td>
<td>A comparator rate created for each acute care facility in the IPC Surveillance on-line dashboards and reporting modules, to guide efforts to reduce healthcare-associated infections. The IPC baseline is based on reported monthly rates for the previous fiscal year. The calculation excludes the monthly rates higher than 1 Standard Deviation above the 12 month average, but includes all rates where the site had optimal performance. This calculation method biases the IPC baseline rate towards zero, to focus on the best patient safety outcomes.</td>
</tr>
<tr>
<td>Patient Admission</td>
<td>A person admitted to and assigned a bed in a hospital by the order of a physician, for the provision of diagnostic or treatment services or both. Includes any time in the emergency department where the patient is subsequently transferred to an inpatient unit. This is the denominator used for non-hospital-acquired rates (see Rate Calculation Section) (Government of Alberta, 2020).</td>
</tr>
<tr>
<td>Patient days</td>
<td>As defined by AHS, this is used to create the denominator for hospital-acquired or hospital-identified cases. The total is equal to midnight census with patients admitted and discharged on the same day counted as a one day stay. It includes patients out on a pass. Day of admission is counted but the day of separation (discharge, death or transfer out of hospital) is not counted. Patient-days are included for inpatient encounters where discharge date is not recorded in the data source. Inpatient totals exclude the time patients are waiting in the emergency department for an inpatient bed (time from decision to admit to discharge from emergency department).</td>
</tr>
<tr>
<td>Emergency department inpatient days (EDIP)</td>
<td>As defined by AHS, denominators for provincial surveillance modules include these figures in the total patient-days. Includes the number of acute care inpatient patient-days utilized in the emergency department during the reporting period. The figures reflect the time from emergency department discharge (i.e. decision to admit) to emergency department departure for patients admitted to an acute care hospital. It is calculated as [\frac{(\text{emergency department departure date and time} - \text{emergency department discharge date and time})}{60 \div 24}]. Figures exclude cases where the emergency department discharge date and time or emergency department departure date and time were not provided or the value has a negative number.</td>
</tr>
</tbody>
</table>
Appendix C: CPO classification algorithm

Is the patient currently admitted to an AHS/COV facility?

Yes → Is this the first time this CPO has been identified from an in-patient?

Yes → Is there an epi link for this CPO to AHS/COV facility in past 12 months?

No → Was the culture Collected ≥ three calendar days after Admission

AND

1) No known colonization with this CPO at time of admission OR

2) An infection with this CPO was not present/incubating on admission

Was the culture Collected ≥ three calendar days after Admission

AND

1) No known colonization with this CPO at time of admission OR

2) An infection with this CPO was not present/incubating on admission

Identified On Admission (OA)

Yes → Hospital-acquired (HA)

No → Hospital-identified (HI)

IDENTIFY ALL RISK FACTORS THAT APPLY:

Travel Outside Alberta
Travel outside Alberta in past 12 months:
1. With healthcare exposure
2. Without healthcare exposure

Epidemiological Link In Alberta
In the past 12 months:
E.g. Community CPO epi link

AHS/COV Healthcare Exposure
In the past 12 months:
1. Previous admission of ≥ three calendar days at an AHS/COV facility with NO known CPO epi link
2. Resident of Alberta long term care facility
3. Indwelling catheter/medical device
4. Surgical procedure, peritoneal dialysis, hemodialysis

1Calendar day one is the day of hospital admission
2Does not include AHS/COV facilities

Approved: January 2012
Revised: June 2020